Relationships of Elevated Systemic Pentraxin-3 Levels With High-Risk Coronary Plaque Components and Impaired Myocardial Perfusion After Percutaneous Coronary Intervention in Patients With ST-Elevation Acute Myocardial Infarction

Kimura, Shigeki; Inagaki, Hiroshi; Haraguchi, Go; Sugiyama, Tomoyo; Miyazaki, Toru; Hatano, Yu; Yoshikawa, Shunji; Ashikaga, Takashi; Isobe, Mitsuaki

doi:10.1253/circj.cj-13-0329

Cited by 27 publications

(34 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Impaired myocardial reperfusion has been shown to be a powerful predictor of poor outcomes, even after successful recanalization. 13 Our findings suggest that in patients with inferior AMI, greater ST-segment depression in lead aVR (ie, ST-segment elevation in lead -aVR) is useful for identifying high-risk patients most likely to benefit from aggressive therapeutic strategies designed to improve myocardial reperfusion.…”

Section: Identification Of High-risk Patients With a Larger Area At Riskmentioning

confidence: 76%

Implications of Using the Cabrera Sequence for Diagnosing Acute Coronary Syndrome

Kosuge

Kimura

2016

Circ J

View full text Add to dashboard Cite

The 12-lead electrocardiogram (ECG) is the important, initial examination for diagnosing acute coronary syndrome (ACS). In the traditional 12-lead ECG display, the precordial leads are displayed in their anatomically contiguous order, which makes it easy to understand the positional relationships between the precordial leads and the heart, but the limb leads are not. The "Cabrera sequence" displays the limb leads in an anatomically contiguous manner, which facilitates understanding of the positional relations between the limb leads and the heart, resulting in more rapid, easy, and accurate ECG interpretation than the traditional limb leads display. This review explores the clinical advantages of the Cabrera sequence as compared with the traditional limb leads display for the diagnosis of ACS. (Circ J 2016; 80: 1087 -1096

show abstract

Section: Identification Of High-risk Patients With a Larger Area At Riskmentioning

confidence: 76%

Implications of Using the Cabrera Sequence for Diagnosing Acute Coronary Syndrome

Kosuge

Kimura

2016

Circ J

View full text Add to dashboard Cite

show abstract

“…In particular, the PTX3 level might reflect atherosclerotic activity, local inflammatory status, and plaque instability at the coronary culprit site more directly than other biomarkers. 7 In addition to the changes in plaque components, coronary vessel volumes were reduced in the EPA group more than in the control group, which also reflected the anti-inflammatory effect of EPA.…”

mentioning

confidence: 89%

Eicosapentaenoic Acid Added to Strong Statin Therapy

Komatsu

Tanaka

2016

Circ J

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp this study are consistent with the findings of the previous study. In terms of inflammatory markers, coronary sinus levels of pentraxin (PTX) 3 and monocyte chemoattractant protein (MCP)-1 were reduced by treatment with EPA. These 2 markers are known to be associated with the mechanism of many inflammatory diseases. In particular, the PTX3 level might reflect atherosclerotic activity, local inflammatory status, and plaque instability at the coronary culprit site more directly than other biomarkers. 7 In addition to the changes in plaque components, coronary vessel volumes were reduced in the EPA group more than in the control group, which also reflected the anti-inflammatory effect of EPA.Regarding the anti-inflammatory effects of EPA, Niki et al explain that its mechanisms were associated with prostaglandins, leukotrienes, nuclear factor κ-B, and peroxisome proliferator activated receptor γ . 3 PTX3 and MCP-1 levels were reduced in coronary sinus samples after EPA treatment, but not in femoral vein samples. These results suggest that EPA could improve the inflammation of coronary artery plaques. Recent studies have documented the efficacy of EPA in diseases other than coronary artery disease through improvement of inflammation. EPA prevented abdominal aortic aneurysm Beneficial Effects of EPA Statin monotherapy is widely prescribed to treat elevated levels of low-density lipoprotein (LDL) cholesterol and the beneficial effects on clinical outcomes in patients with cardiovascular diseases are recognized worldwide. However, patients have a residual risk despite highly effective statin therapy. A number of studies have been conducted over 10 years to explore the effects of adding other treatments to statins, called 'Beyond Statin', such as niacin, cholesteryl ester transfer protein inhibitors, ezetimibe, and eicosapentaenoic acid (EPA). Article p 450The JELIS trial reported that EPA was a promising treatment for the prevention of major coronary events in Japanese hypercholesterolemic patients. 1 In that study, 18,645 patients (14,981 in primary prevention and 3,664 in secondary prevention) with hypercholesterolemia were randomly assigned to receive either 1,800 mg of EPA daily with a statin (EPA group; n=9,326) or a statin only (controls; n=9,319) with a 5-year follow-up. A 19% relative reduction in major coronary events was observed in the EPA group (P=0.011), and serum LDL cholesterol was not a significant factor in the reduction of risk for major coronary events. In the secondary prevention subgroup given EPA treatment, major coronary events were reduced by 19% (P=0.048). However, the JELIS trial did not include patients treated with strong statins.It has been reported that in the patients with coronary artery disease treated with a strong statin, the changes in destabilized components of coronary artery plaques evaluated by virtual histology intravascular ultrasound correlated negatively with the EPA to arachidoni...

show abstract

“…Pentraksyna 3 jako czynnik prognostyczny w chorobie wieńcowej U pacjentów ze stabilną chorobą wieńcową wyższe stęże-nia PTX3 są związane ze zwiększonym ryzykiem zdarzenia sercowo-naczyniowego -zawału serca, udaru mózgu, zgonu z przyczyn sercowo-naczyniowych, incydentu zaostrzenia niewydolności serca -oraz zwiększoną śmiertelnością całkowitą [20]. Po zawale serca z uniesieniem odcinka ST (STEMI, ST-elevation myocardial infarction) leczonym przezskórną interwencją wieńcową (PCI, percutaneous były niezależnym czynnikiem prognostycznym śmiertelności [34]. W grupie chorych ze STEMI leczonych pierwotną PCI (pPCI, primary PCI) PTX3 jest niezależnym markerem rozwoju niewydolności lewej komory oraz śmiertelności 30-dniowej i rocznej.…”

Section: Pentraksyna 3 W Diagnostyce Ostrych Zespołów Wieńcowychunclassified

“…coronary intervention) wysokie stężenia PTX3 przed PCI wiążą się z nieprawidłową perfuzją mięśnia sercowego po zabiegu, co jest uznanym czynnikiem niekorzystnego rokowania u pacjentów z ACS. W 9-miesięcznej obserwacji pacjenci z wyższymi stężeniami PTX3 przed PCI i nieprawidłową perfuzją po zabiegu (0-1 w skali MBG [Myocardial Blush Grade]) istotnie częściej doznawali niekorzystnych zdarzeń sercowo-naczyniowych [34]. Wyższe wyjściowo stężenie PTX3 wiąże się z częstszym występowaniem powtórnych incydentów sercowo-naczyniowych.…”

Section: Konflikt Interesówunclassified

Pentraksyna 3 jako niezależny marker rozwoju choroby wieńcowej, stopnia jej zaawansowania oraz rokowania

et al. 2017

View full text Add to dashboard Cite

Relationships of Elevated Systemic Pentraxin-3 Levels With High-Risk Coronary Plaque Components and Impaired Myocardial Perfusion After Percutaneous Coronary Intervention in Patients With ST-Elevation Acute Myocardial Infarction

Cited by 27 publications

References 31 publications

Implications of Using the Cabrera Sequence for Diagnosing Acute Coronary Syndrome

Implications of Using the Cabrera Sequence for Diagnosing Acute Coronary Syndrome

Eicosapentaenoic Acid Added to Strong Statin Therapy

Pentraksyna 3 jako niezależny marker rozwoju choroby wieńcowej, stopnia jej zaawansowania oraz rokowania

Contact Info

Product

Resources

About